Literature DB >> 32447436

Articles provided insufficient information to conduct an appropriate retrospective assessment of the pragmatic/explanatory features of medicine trials with the PRECIS-2 tool.

Rafael Dal-Ré1.   

Abstract

PURPOSE: To assess whether, in the retrospective assessment of the pragmatic/explanatory features of pragmatic randomized controlled trials (pRCTs), the nine PRECIS-2 domain scores using the information provided in articles were modified after using the information reported in other publicly available sources.
METHODS: This is a cross-sectional study of participant-level pRCTs published in July 2018 to December 2019 in the four highest-impact general medicine journals. The articles described the main results of pRCTs assessing medicines in one or more arms that were not in the pre-licensing phases. The information reported in trial full protocols, published protocols, and other publications, registries, and trial websites were assessed and scored, and compared with that previously obtained after reviewing the information reported in the articles.
RESULTS: Out of 76 articles on pRCTs, 13 (17%) were included in the analysis. All were two-arm trials, assessing medicines only (n = 7), medicine vs device (n = 2), medicine vs surgery (n = 1), or medicine vs placebo (n = 3). Seven were open-label trials, and six had any type of masking. All except one had the full protocol available and/or published protocol; seven had other types of publication available. The assessment of the nine PRECIS-2 domains with the information reported in the 13 articles was changed in all trials after using the information included in other additional available sources. Between one (n = 1 article) and six (n = 2) domains were modified in each pRCT. The domains that most commonly changed were "organization" (n = 12), "recruitment" (n = 11), and "follow-up" (n = 8). "Primary outcome" and "primary analysis" were not modified in any trial. Eight percent of all domains could not be assessed due to inadequate or lack of information in seven articles; those were "recruitment" (n = 3), "organization" (n = 3), "setting" (n = 2), and "flexibility:adherence" (n = 1).
CONCLUSION: Articles describing the trial main results are usually insufficient for the appropriate retrospective assessment of the pragmatic/explanatory features of a pRCT by authors not involved in the conduct of the trial. To address this issue, editors should require the submission of the original full protocol and final full protocol with the history of amendments to be published as supplementary material to the article.

Entities:  

Keywords:  Assessment; Explanatory; Medicines; PRECIS-2; Pragmatic; Protocol; Randomized controlled trials; Trial main results

Mesh:

Year:  2020        PMID: 32447436     DOI: 10.1007/s00228-020-02901-4

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  5 in total

1.  The PRECIS-2 tool seems not to be useful to discriminate the degree of pragmatism of medicine masked trials from that of open-label trials.

Authors:  Rafael Dal-Ré
Journal:  Eur J Clin Pharmacol       Date:  2020-10-26       Impact factor: 2.953

2.  Informed consent in pragmatic trials: results from a survey of trials published 2014-2019.

Authors:  Jennifer Zhe Zhang; Stuart G Nicholls; Kelly Carroll; Hayden Peter Nix; Cory E Goldstein; Spencer Phillips Hey; Jamie C Brehaut; Paul C McLean; Charles Weijer; Dean A Fergusson; Monica Taljaard
Journal:  J Med Ethics       Date:  2021-11-15       Impact factor: 5.926

Review 3.  A review of pragmatic trials found a high degree of diversity in design and scope, deficiencies in reporting and trial registry data, and poor indexing.

Authors:  Stuart G Nicholls; Kelly Carroll; Spencer Phillips Hey; Merrick Zwarenstein; Jennifer Zhe Zhang; Hayden P Nix; Jamie C Brehaut; Joanne E McKenzie; Steve McDonald; Charles Weijer; Dean A Fergusson; Monica Taljaard
Journal:  J Clin Epidemiol       Date:  2021-03-28       Impact factor: 6.437

4.  An application of PRECIS-2 to evaluate trial design in a pilot cluster randomised controlled trial of a community-based smoking cessation intervention for women living in disadvantaged areas of Ireland.

Authors:  Catherine Darker; Kirsty Loudon; Nicola O'Connell; Stefania Castello; Emma Burke; Joanne Vance; Caitriona Reynolds; Aine Buggy; Nadine Dougall; Pauline Williams; Fiona Dobbie; Linda Bauld; Catherine B Hayes
Journal:  Pilot Feasibility Stud       Date:  2022-01-25

5.  Ethical considerations within pragmatic randomized controlled trials in dementia: Results from a literature survey.

Authors:  Stuart G Nicholls; Kelly Carroll; Hayden P Nix; Fan Li; Spencer Phillips Hey; Susan L Mitchell; Charles Weijer; Monica Taljaard
Journal:  Alzheimers Dement (N Y)       Date:  2022-05-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.